Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR2 | O95665 | 17/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 17/20 | 0.53 |
| ▸ | SORT1 | Q99523 | 16/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31657668 | 0.89 | RAMP3 (0.48) | NTSR2NTSR1SORT1 | |
| SCHEMBL32677400 | 0.87 | CXCR4 (0.47) | NTSR2NTSR1SORT1 | |
| SCHEMBL32677398 | 0.87 | CXCR4 (0.47) | NTSR2NTSR1SORT1 | |
| SCHEMBL32677417 | 0.87 | CXCR4 (0.47) | NTSR2NTSR1SORT1 | |
| SCHEMBL8365216 | 0.87 | NPY2R (0.50) | NTSR2NTSR1SORT1MAPK8MAPK9 | |
| SCHEMBL31235877 | 0.87 | NPY1R (0.52) | NTSR2NTSR1SORT1MAPK8MAPK9 | |
| SCHEMBL30974226 | 0.87 | RAMP3 (0.50) | MAPK8MAPK9MAPK10 | |
| SCHEMBL30171123 | 0.87 | RAMP3 (0.51) | NTSR2NTSR1SORT1MAPK8MAPK9 | |
| SCHEMBL30338867 | 0.86 | MAPK8 (0.53) | MAPK8MAPK9MAPK10 | |
| SCHEMBL30799320 | 0.86 | RAMP3 (0.50) | NTSR2NTSR1SORT1PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057917-A1 | COMPOSITION AND METHODS FOR TREATING RADIATION INDUCED INJURY | XEQUEL BIO INC (US) | 2025-02-20 | — | — | US | disclosed |
| US-20230147795-A1 | COMPOSITION AND METHODS FOR PREVENTING RADIATION INJURY AND PROMOTING TISSUE REGENERATION | XEQUEL BIO, INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147795-A1 | COMPOSITION AND METHODS FOR PREVENTING RADIATION INJURY AND PROMOTING TISSUE REGENERATION | MMP1, COL2A1, MMP8 | NTSR2 2853/4885NTSR1 2603/4885SORT1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.